home / stock / calt / calt news


CALT News and Press, Calliditas Therapeutics AB From 04/10/24

Stock Information

Company Name: Calliditas Therapeutics AB
Stock Symbol: CALT
Market: NASDAQ

Menu

CALT CALT Quote CALT Short CALT News CALT Articles CALT Message Board
Get CALT Alerts

News, Short Squeeze, Breakout and More Instantly...

CALT - How To Trade (CALT)

2024-04-10 07:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CALT - Calliditas Therapeutics to Attend Conferences in April

Calliditas Therapeutics to Attend Conferences in April PR Newswire STOCKHOLM , April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announc...

CALT - Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires PR Newswire STOCKHOLM , April 8, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), t...

CALT - Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment

Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment PR Newswire STOCKHOLM , April 8, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") toda...

CALT - Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®

Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® PR Newswire SHANGHAI , March 11, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

CALT - Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®

Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO® PR Newswire STOCKHOLM , March 6, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the ...

CALT - Calliditas Therapeutics to Attend Investor Conferences in March

Calliditas Therapeutics to Attend Investor Conferences in March PR Newswire STOCKHOLM , March 1, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases t...

CALT - Long Term Trading Analysis for (CALT)

2024-02-29 16:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CALT - Calliditas Therapeutics AB (publ) (CALT) Q4 2023 Earnings Call Transcript

2024-02-21 17:46:07 ET Calliditas Therapeutics AB (publ) (CALT) Q4 2023 Earnings Call Transcript February 21, 2024, 08:30 AM ET Company Participants Renee Aguiar-Lucander - CEO Richard Philipson - CMO Maria Tornsen - President, North America Fredrik Johansson...

CALT - Expected US Company Earnings on Wednesday, February 21st, 2024

Vimeo Inc. (VMEO) is expected to report $-0.01 for Q4 2023 Heineken N.V ADR (HEINY) is expected to report for Q4 2023 American States Water Company (AWR) is expected to report $0.53 for Q4 2023 NextPlay Technologies Inc. (NXTP) is expected to report for Q3 2024 Inseego Corp. (INSG...

Previous 10 Next 10